Daniel Stegman
Family Medicine · Tulsa, OKNPI 1396249082
Payments from drug & device makers
Across 142 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$426
- Lilly USA, LLC$373
- Insulet Corporation$315
- AbbVie$219
- GSK$180
- Amgen$170
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $426 |
| Lilly USA, LLC | 8 | $373 |
| Insulet Corporation | 2 | $315 |
| AbbVie | 8 | $219 |
| GSK | 6 | $180 |
| Amgen | 11 | $170 |
| AstraZeneca | 3 | $160 |
| Boehringer Ingelheim | 8 | $148 |
| Johnson & Johnson | 2 | $143 |
| Daiichi Sankyo Inc. | 7 | $133 |
| Pfizer | 9 | $132 |
| Pharmacosmos Therapeutics Inc. | 2 | $109 |
| Mylan Specialty L.p. | 7 | $107 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $98 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Bayer | 4 | $56 |
| Exact Sciences | 3 | $47 |
| Astellas Pharma US Inc | 1 | $32 |
| Merck | 2 | $32 |
| Novartis | 2 | $30 |
| Viatris Specialty LLC | 2 | $30 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Medtronic | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Inari Medical, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Antares Pharma, Inc. | 1 | $16 |
| SK Life Science, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Biogen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,249 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 149 | $211,586 |
| FarxigaDapagliflozin Propanediol | 137 | $136,425 |
| JardianceEmpagliflozin | 105 | $104,317 |
| EliquisApixaban | 108 | $100,281 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $63,708 |
| XareltoRivaroxaban | 45 | $49,305 |
| TrulicityDulaglutide | 27 | $43,197 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 29 | $37,816 |
| MounjaroTirzepatide | 30 | $36,990 |
| LinzessLinaclotide | 33 | $35,640 |
| JanuviaSitagliptin Phosphate | 40 | $34,708 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $29,349 |
| VraylarCariprazine Hcl | 17 | $28,560 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $22,548 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $15,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $426 | $211,586149 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $160 | $181,414193 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Stiolto Respimat | $148 | $173,442163 claims |
| PfizerEliquis, Abrysvo | $132 | $113,561150 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $373 | $80,18657 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $180 | $76,57475 claims |
| AbbVieLinzess, Vraylar | $219 | $64,20050 claims |
| Johnson & JohnsonXarelto | $143 | $49,30545 claims |
| MerckJanuvia | $32 | $34,70840 claims |
| NovartisEntresto | $30 | $14,85821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $27 | $12,00714 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $9,46211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Tulsa
- Jeffrey ChasteenTulsa$820K
- Brooke DunlavyTulsa$572K
- Geoffrey PlumleeTulsa$297K
- Jonathan McGheeTulsa$231K
- Kimberly HuttonTulsa$76K
- Sarah HallTulsa$52K
- Larissa GiulianoTulsa$36K
- Candy TingTulsa$28K
- Scott GhereTulsa$27K
- Michael MaddoxTulsa$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.